Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
Monique M R de MaatHenk J van LeeuwenElisabeth A RooversSabine J G M AhlersJolanda LambersMarcel M C HovensPublished in: BMC pharmacology & toxicology (2024)
Retrospectively registered, ClinicalTrials.gov ID NTC 05926518 g, date of registration 06/01/23, unique ID 2020/1725.